Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
BioNTech SE, headquartered in Mainz, Germany, is a leading player in the Research and Development sector of biotechnology, excluding nanobiotechnology. Founded in 2008, the company has made significant strides in mRNA technology, particularly in the development of innovative therapies and vaccines for infectious diseases and cancer.
With a strong focus on personalised medicine, BioNTech's core products include its groundbreaking mRNA-based vaccines, which gained global recognition during the COVID-19 pandemic. The company has established itself as a pioneer in the biotechnology field, achieving notable milestones such as the rapid development of its COVID-19 vaccine in collaboration with Pfizer.
BioNTech's commitment to advancing healthcare solutions positions it as a formidable entity in the biotechnology landscape, with a robust pipeline of therapeutic candidates aimed at addressing unmet medical needs.
+23 vs industry average
Biontech’s score of 48 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research and Development in Biotechnology (except Nanobiotechnology) has below-average carbon intensity
The Research and Development in Biotechnology (except Nanobiotechnology) industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
In 2025, BioNTech, headquartered in DE, reported approximately 711.6 million kg CO2e in total emissions. This figure comprises roughly 2.2 million kg CO2e for Scope 1 emissions and approximately 5.8 million kg CO2e for Scope 2 emissions. Scope 3 emissions were the largest contributor, totalling around 703.6 million kg CO2e.
For 2024, BioNTech's total emissions were approximately 892.9 million kg CO2e. This includes about 2.4 million kg CO2e in Scope 1 emissions and approximately 4 million kg CO2e in Scope 2 emissions. Scope 3 emissions accounted for roughly 886.4 million kg CO2e.
In 2023, the company reported total emissions of approximately 534.2 million kg CO2e, with Scope 1 emissions at about 1.3 million kg CO2e and Scope 2 emissions at approximately 3.3 million kg CO2e. Scope 3 emissions for that year were approximately 529.5 million kg CO2e.
BioNTech has committed to an ambitious climate target: an absolute reduction of 42% in Scope 1 and 2 greenhouse gas emissions by 2030, using 2021 as the baseline year. This commitment aligns with Science Based Targets initiative (SBTi) requirements for near-term targets. Furthermore, BioNTech aims to ensure that 72% of its suppliers, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets in place by 2027.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 1
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. BioNTech commits that 72% of its supplier…
2030
42% reduction in Scope 2
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. BioNTech commits that 72% of its supplier…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


Common questions about Biontech’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more